LA-PF4 Inhibitors
LA-PF4 inhibitors are a class of chemical compounds that specifically target the interaction between platelet factor 4 (PF4) and lipids, primarily those involved in lipid antigen presentation (LA). PF4 is a chemokine that plays a significant role in modulating immune responses, platelet aggregation, and inflammation. It is also known to interact with various lipid molecules, influencing processes such as coagulation and cellular signaling. Inhibiting the interaction of LA with PF4 disrupts the formation of PF4-lipid complexes, which can be pivotal in understanding the pathways involved in immune regulation, especially in the context of inflammation and platelet biology. LA-PF4 inhibitors allow researchers to study how lipid-PF4 interactions contribute to broader biological systems such as immune signaling, coagulation cascades, and platelet function.
In research settings, LA-PF4 inhibitors are used to dissect the molecular pathways associated with PF4-lipid binding and how this interaction influences cellular processes. By inhibiting these complexes, researchers can explore the role of PF4 in regulating lipid antigen presentation and how it affects immune cell activation, cytokine release, and platelet activation. Additionally, these inhibitors provide valuable insights into the mechanisms of lipid-mediated signaling pathways, allowing for a deeper understanding of how lipid-protein interactions can regulate immune responses and hemostasis. LA-PF4 inhibitors thus serve as important molecular tools for investigating the functional roles of PF4 beyond platelet biology, extending into areas such as lipid metabolism and immune system regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $102.00 | 6 | |
Hydrocortisone may downregulate LA-PF4 expression by binding to glucocorticoid receptors, which can suppress pro-inflammatory cytokine transcription. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A is posited to inhibit the nuclear factor NF-κB, potentially leading to a decrease in LA-PF4 transcription due to its role in the inflammatory cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 may reduce LA-PF4 synthesis by inhibiting p38 MAPK, an enzyme that facilitates the production of inflammatory mediators, including chemokines. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 has the potential to decrease LA-PF4 transcription by inhibiting PI3K, which plays a pivotal role in the activation of downstream pathways that contribute to inflammation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin could reduce LA-PF4 expression primarily by inhibiting the mTOR pathway, which is instrumental in controlling cell growth and cytokine production. | ||||||
Roflumilast | 162401-32-3 | sc-208313 | 5 mg | $60.00 | 21 | |
Roflumilast potentially reduces LA-PF4 expression through inhibition of PDE4, thereby increasing intracellular cAMP, which can have a suppressive effect on pro-inflammatory cytokine release. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid could lead to decreased LA-PF4 production by inhibiting histone deacetylases (HDACs), altering chromatin accessibility and reducing gene transcription rates. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod might decrease LA-PF4 expression by acting as an antagonist to Toll-like receptors, which play a key role in initiating immune responses that include chemokine production. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
Stattic is theorized to inhibit STAT3 activation, thereby potentially reducing the expression of LA-PF4, as STAT3 is involved in the upregulation of genes during inflammatory responses. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 could suppress LA-PF4 expression by inhibiting BRD4, a member of the BET protein family, which is required for the transcription of several genes involved in inflammation. | ||||||